We believe a new genetically-targeted therapy to treat a type of motor neurone disease (MND) could be a game changer, after results of a Phase 3 clinical trial showed significant improvement in patients’ symptoms of the debilitating disease after 12 months. MND, also known as amyotrophic lateral sclerosis (ALS) is a disorder that affects the […]